Silvia Paoletta

This inventor holds 7 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignees: Cancer Research Technology Limited, Cellcentric Limited. Active years: 2020-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Silvia Paoletta. Retrieved from https://idiyas.com/inventor/silvia-paoletta

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 3

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 7.1

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

4 out of 268

Cancer Research Technology Limited

Years Active: 2020-2023

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11661423 - Heterocyclic compounds as RET kinase inhibitors (2023-05-30),

2. 11548896 - Heterocyclic compounds as RET kinase inhibitors (2023-01-10),

3. 11377443 - Pharmaceutical compounds (2022-07-05),

4. 10954241 - Heterocyclic compounds as ret kinase inhibitors (2021-03-23),

5. 10844067 - Heterocyclic compounds as RET kinase inhibitors (2020-11-24),

6. 10696666 - Pharmaceutical compounds (2020-06-30),

7. 10647704 - Pharmaceutical compounds (2020-05-12),

Title: The Innovative Contributions of Silvia Paoletta

Introduction

Silvia Paoletta is a prominent inventor based in Nottingham, GB, known for her significant contributions to the field of pharmaceutical sciences. With a total of seven patents to her name, she has made remarkable strides in the development of compounds that target critical biological processes.

Latest Patents

Among her latest patents are innovative heterocyclic compounds that serve as RET kinase inhibitors. These compounds are designed to inhibit the activity of the RET kinase enzyme, which is implicated in various proliferative disorders, including cancer. The patents detail the processes for preparing these compounds, their pharmaceutical compositions, and their potential applications in treating diseases associated with RET kinase activity.

Career Highlights

Silvia has worked with notable organizations such as Cancer Research Technology Limited and Cellcentric Limited. Her work in these companies has been instrumental in advancing research and development in cancer therapies.

Collaborations

Throughout her career, Silvia has collaborated with esteemed colleagues, including Allan Michael Jordan and Rebecca Newton. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Silvia Paoletta's contributions to the field of pharmaceutical sciences through her patents and collaborations highlight her role as a leading inventor. Her work continues to impact the development of treatments for serious health conditions, showcasing the importance of innovation in medicine.

Profile summary based on public USPTO records.